ribupatide vs THDBH120
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline
ribupatide
Developed by Kailera Therapeutics under a licence from Jiangsu Hengrui Pharmaceuticals
NCT06396429 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 567 participants. The sponsor reports weight loss of up to 17.7% with ribupatide, 16.3 percentage points more than placebo, with up to 88.0% of treated participants losing at least 5% of body weight, and describes the trial as positive.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2026 · NCT06974851 (registry estimate)
Reported efficacy
Percentage change from baseline in weight after 48 weeks of treatment (Baseline, Week 48); Proportion of subjects with weight loss of≥5% from baseline after 48 weeks of treatment (Week 48): Mean weight loss at Week 48 (treatment policy estimand): up to 17.7% with HRS9531 (16.3 percentage points placebo-adjusted); up to 88.0% of HRS9531-treated participants achieved at least 5% weight loss (met)
Result source: NCT06396429
THDBH120
Developed by Tonghua Dongbao Pharmaceutical
NCT06951945 · Phase 1 · completed
The trial was randomized, double-blind, and placebo-controlled, which is a sound design. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants with One or More Adverse Event(s) and Serious Adverse Event(s)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
Number of Participants with One or More Adverse Event(s) and Serious Adverse Event(s) (78 days): Phase Ib multiple-dose, randomized, double-blind, placebo-controlled study: THDBH120 led to weight loss of up to 9.36% at six weeks. The two lower-dosed regimens led to weight loss of 7.38% after four weeks and 8.03% after six. Three dosing regimens that involved increasing doses every two or four weeks all showed significance against placebo. (not_applicable)
Result source: NCT06951945
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ribupatide | THDBH120 |
|---|---|---|
| Body weight, % change | —Not posted · NCT06396429 | —Not reported |
| Weight loss of 5% or more | —Not posted · NCT06396429 | —Not reported |
| Weight loss of 10% or more | —Not posted · NCT06396429 | —Not reported |
| Waist circumference, change (cm) | —Not posted · NCT06396429 | —Not reported |
Body weight, % change
- ribupatide
- —Not posted · NCT06396429
- THDBH120
- —Not reported
Weight loss of 5% or more
- ribupatide
- —Not posted · NCT06396429
- THDBH120
- —Not reported
Weight loss of 10% or more
- ribupatide
- —Not posted · NCT06396429
- THDBH120
- —Not reported
Waist circumference, change (cm)
- ribupatide
- —Not posted · NCT06396429
- THDBH120
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
THDBH120: no structured comparison results are available for Obesity.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
ribupatide
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ribupatide's landscape · THDBH120's landscape